NCT05746611View on ClinicalTrials.gov

Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein

PHASE4CompletedINTERVENTIONAL
Enrollment

7,500

Participants

Timeline

Start Date

April 17, 2023

Primary Completion Date

May 13, 2024

Study Completion Date

May 13, 2024

Conditions
Latent Tuberculosis Infection
Interventions
BIOLOGICAL

Recombinant Mycobacterium tuberculosis fusion protein for injection

For the suction test, EC0.1ml was injected into the palmar skin of the forearm by the Mondu's method

BIOLOGICAL

TB-PPD was injected

For the aspiration test, 0.1ml TB-PPD was injected into the palmar skin of the forearm by the Mondu's method

Trial Locations (1)

545000

Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Liuzhou

All Listed Sponsors
lead

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

INDUSTRY